Nanomedicine Approach Could Offer New Way to Target HER2+ Breast Cancer
Novel research suggests that using a nano-molecularly imprinted polymer may offer a unique and effective way to treat HER2+ breast cancer.
Authors: Md Pauzi SH, Saari HN, Roslan MR, Syed Khair Azman Jamalulil SNS, Tauan IS, Mohd Rusli FA, Aizuddin AN Abstract INTRODUCTION: Evaluation of HER2 status in breast cancer using immunohistochemistry (IHC) and in-situ-hybridisation (ISH) study is important to establish prognosis and to select patient for targeted therapy. OBJECTIVE: The study aims to determine the concordance between HER2 protein IHC score and its gene status by dual-colour dual-hapten in-situ-hybridization (DDISH) study. MATERIALS AND METHODS: Retrospective study was performed on 767 referred breast cancer cases over a period of five ...
Publication date: Available online 20 August 2019Source: Academic RadiologyAuthor(s): Laura Heacock, Alana Lewin, Abimbola Ayoola, Melanie Moccaldi, James S. Babb, Sungheon G. Kim, Linda MoyRationale and ObjectivesPathologic complete response (pCR) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after HER2-targeted therapy correlates increased disease-free survival and decreased mastectomy rates. The aim of this study was to explore tumor shrinkage patterns and initial tumor enhancement with pCR in HER2-positive breast cancer.Materials and MethodsThis was an institutional review boar...
Conditions: Breast Cancer; Solid Tumor Intervention: Drug: OBT076, a CD205-directed antibody-drug conjugate Sponsor: Oxford BioTherapeutics Ltd Recruiting
Condition: Metastatic Breast Cancer Intervention: Drug: Nivolumab Sponsors: Seoul National University Hospital; Seoul National University Bundang Hospital; Korean Cancer Study Group (KCSG); Eisai Korea; Ono pharmaceutical Korea Recruiting
CONCLUSIONS: This multicentric retrospective study confirmed that sequential adjuvant therapy with anthracycline-based chemotherapy and paclitaxel for HER2 negative breast cancer is an effective and reliable regimen. PMID: 31424664 [PubMed - in process]
CONCLUSIONS: Our study highlights the difficulty encountered during HER2 testing using immunohistochemistry and CISH. This also emphasizes the need for rigorous quality control procedures for specimen preparation and analysis. PMID: 31424659 [PubMed - in process]
There are two main types of HER2-negative breast cancer: hormone receptor-positive and triple-negative. Many treatments exist, and prognosis varies. Learn more here.
ConclusionTogether these results emphasize an anti-tumorigenic role with a potential therapeutic value for PRL in HER-2 and luminal B breast cancer subtypes targeting the cancer stem-like cells.
Condition: Breast Cancer Interventions: Drug: Ipatasertib; Drug: Placebo; Drug: Palbociclib; Drug: Fulvestrant Sponsor: Hoffmann-La Roche Not yet recruiting
CONCLUSIONS: The most potential impact of TAILORx findings on practice change is for patients ≤ 50 years of age with RS of 16-25 who did not receive chemotherapy but may benefit. These findings may serve as a baseline for future analysis of practice patterns related to TAILORx. PMID: 31429016 [PubMed - as supplied by publisher]